

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

21 Jun 2026

### Evaluation of the effect of vaginal Progesterone in preventing preterm labor

#### Protocol summary

##### Summary

This is a randomized double blind clinical trial in preventing preterm labor. Inclusion criteria were: 26-36 weeks of gestation, intact membrane and confirmed preterm labor. Exclusion criteria were: disruption of treatment, lack of sufficient data and occurrence of preeclampsia. During the study course, subjects were in their 26-36 weeks of gestation with a diagnosis of preterm labor referring to Al-Zahra maternity hospital. Two hundred and sixty women were randomly assigned into the two groups. All underwent routine management of preterm labor and signed a formal consent. Subjects received either progesterone or placebo. Once a parturient was labeled as preterm, she was given a vaginal suppository. After two hours the subject was examined for cessation of labor pain. If no contraction was detected, the woman was sent to a prelabor control ward, with hydration and relative Bed Rest order. She was given a vaginal supp. per day and was discharged after 24 hours from discontinuation of contractions. They were warned against excessive physical activity and advised for prompt referral in case of labor pain. Vaginal supp should be continued till 36 weeks gestation. The aim of the study was to compare the rate of days in delay of delivery and so, maternal and neonatal complication in both groups.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT138706051096N1**  
Registration date: **2009-02-20, 1387/12/02**  
Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2009-02-20, 1387/12/02

##### Registrant information

###### Name

Seyede Hajar Sharami

###### Name of organization / entity

Guilan University of Medical Science

###### Country

Iran (Islamic Republic of)

###### Phone

+98 13 1322 5624

###### Email address

sharami@gums.ac.ir

##### Recruitment status

###### Recruitment complete

##### Funding source

vice chancellor for research-Guilan University of Medical Sciences

##### Expected recruitment start date

2009-01-22, 1387/11/03

##### Expected recruitment end date

2010-01-23, 1388/11/03

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Evaluation of the effect of vaginal Progesterone in preventing preterm labor

##### Public title

Evaluation of the effect of vaginal Progesterone in preventing preterm labor

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criteria: Pregnant women were eligible to enter

the trial if 1) they were between 26-36 weeks of gestation based on their LMP or sonography before 16 weeks of gestation. 2) Confirmation of premature delivery with a)uterine contractions more than 30 seconds and three or more contractions per 30 minutes established by tochodynamometer b) cervical dilatation of 0-2 cm in nulliparous and 1 -2 cm in multiparous and cervical effacement greater than 50% 3) intact membrane. Exclusion criteria included: 1) unwillingness or inability to comply with study procedures before 36 weeks of gestation 2) lack of useful sufficient data 3) preeclampsia requiring termination of pregnancy.

#### **Age**

From **15 years** old to **50 years** old

#### **Gender**

Female

#### **Phase**

3

#### **Groups that have been masked**

*No information*

#### **Sample size**

Target sample size: **260**

#### **Randomization (investigator's opinion)**

Randomized

#### **Randomization description**

#### **Blinding (investigator's opinion)**

Double blinded

#### **Blinding description**

#### **Placebo**

Used

#### **Assignment**

Parallel

#### **Other design features**

## **Secondary Ids**

### **1**

#### **Registry name**

#### **Secondary trial Id**

#### **Registration date**

2017-11-21, 1396/08/30

## **Ethics committees**

### **1**

#### **Ethics committee**

##### **Name of ethics committee**

Vice chancellor for research-Guilan University of Medical Sciences

##### **Street address**

Vice chancellor for research-Guilan University of Medical Sciences-opposite of Azodi Studium-Namjo street

##### **City**

Rasht

##### **Postal code**

#### **Approval date**

empty

#### **Ethics committee reference number**

6219

## **Health conditions studied**

### **1**

#### **Description of health condition studied**

prevention of preterm labor

#### **ICD-10 code**

O60

#### **ICD-10 code description**

Preterm labour

## **Primary outcomes**

### **1**

#### **Description**

prevention of preterm labour( before 37 weeks)

#### **Timepoint**

2 hours after insertion of suppository, then weekly visit

#### **Method of measurement**

control of uterine contraction

### **2**

#### **Description**

Prevention of preterm labor (before 34 weeks)

#### **Timepoint**

every two weeks

#### **Method of measurement**

Patient visits, uterine contraction determination

## **Secondary outcomes**

### **1**

#### **Description**

Delay of delivery

#### **Timepoint**

post partum

#### **Method of measurement**

documented data

### **2**

#### **Description**

Duration of hospitalization

#### **Timepoint**

post partum (weekly)

#### **Method of measurement**

documented data

### **3**

#### **Description**

Mean of frequency,intensity and duration of contractions

#### **Timepoint**

48 hours after initiation of therapy

#### **Method of measurement**

detected by Tochodynamometer

## 4

### **Description**

Delay of delivery

### **Timepoint**

postpartum

### **Method of measurement**

documented data

## 5

### **Description**

Delay for a week of delivery

### **Timepoint**

after delivery

### **Method of measurement**

documented data

## 6

### **Description**

Low birth weight

### **Timepoint**

after delivery

### **Method of measurement**

documented data

## 7

### **Description**

APGAR score below 7

### **Timepoint**

after delivery

### **Method of measurement**

documented data

## 8

### **Description**

NICU admission

### **Timepoint**

after delivery

### **Method of measurement**

documented data

## 9

### **Description**

Perinatal Mortality

### **Timepoint**

after delivery

### **Method of measurement**

documented data

## 10

### **Description**

Fetal death

### **Timepoint**

after delivery

### **Method of measurement**

documented data

## 11

### **Description**

Neonatal distress

### **Timepoint**

after delivery

### **Method of measurement**

documented data

## 12

### **Description**

Postpartum Retinopathy

### **Timepoint**

after delivery

### **Method of measurement**

documented data

## 13

### **Description**

Necrotizing enterocolitis

### **Timepoint**

after delivery

### **Method of measurement**

documented data

## 14

### **Description**

Neonatal sepsis

### **Timepoint**

after delivery

### **Method of measurement**

documented data

## 15

### **Description**

Intraventricular hemorrhage

### **Timepoint**

after delivery

### **Method of measurement**

documented data

## 16

### **Description**

side effects of progesteron

### **Timepoint**

every two weeks

### **Method of measurement**

interview

## 17

### **Description**

premature rupture of membranes

### **Timepoint**

during delivery

### **Method of measurement**

documented data

## 18

### Description

chorioamnionitis

### Timepoint

after delivery

### Method of measurement

documented data

## 19

### Description

Severe hemorrhage (blood transfusion)

### Timepoint

after delivery

### Method of measurement

documented data

## 20

### Description

Days of hospitalization

### Timepoint

after delivery

### Method of measurement

documented data

## Intervention groups

### 1

#### Description

Intervention group: Progesterone vaginal supp (200 mg); after two hours, the subject was examined for cessation of labor pain. If no contraction was detected she was given a vaginal supp per day.

#### Category

*empty*

### 2

#### Description

Control group: Placebo vaginal supp (200 mg); after two hours, the subject was examined for cessation of labor pain. If no contraction was detected she was given a vaginal supp per day.

#### Category

*empty*

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Al-Zahra hospital,Rasht

##### Full name of responsible person

##### Street address

##### City

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Vice Chancellor for research-Guilan University of Medical Sciences

##### Full name of responsible person

Dr. Abdolrasol Sobhani

##### Street address

Mellat St., Namjoo Ave.

##### City

Rasht

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Vice Chancellor for research-Guilan University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

*empty*

#### Domestic or foreign origin

*empty*

#### Category of foreign source of funding

*empty*

#### Country of origin

#### Type of organization providing the funding

*empty*

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Guilan University of Medical Sciences

##### Full name of responsible person

Dr. Seyede Hajar Sharami

##### Position

Associate professor of Guilan University of Medical Sciences

##### Other areas of specialty/work

##### Street address

Reproduction Health research center-Alzahra hospital-Namjo street

##### City

Rasht

##### Postal code

##### Phone

+98 13 1322 5624

##### Fax

##### Email

Sharami@gums.ac.ir

##### Web page address

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

Guilan University of Medical Sciences

**Full name of responsible person**

Dr.Seyede Hajar Sharami

**Position**

Associated professor-Guilan University of Medical Sciences

**Other areas of specialty/work****Street address**

Reproduction Health research center-Alzahra hospital-Namjo street

**City**

Rasht

**Postal code****Phone**

+98 13 1322 5624

**Fax****Email**

Sharami@gums.ac.ir

**Web page address****Person responsible for updating data****Contact****Name of organization / entity**

Reproduction Health Reseach Center

**Full name of responsible person**

Seyede Fatemeh Dalil Hirati

**Position**

Bs in Midwifery

**Other areas of specialty/work****Street address**

Reproduction Health research center-Alzahra hospital-Namjo street

**City**

Rasht

**Postal code****Phone**

+98 13 1322 5624

**Fax****Email**

H\_fertility@gums.ac.ir

**Web page address****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*